Prostate cancer: Is the future focal?

**Poster Session 57**

**Location:** Room Munich, North Hall (Level 1)

**Chairs:**
- E. Barret, Paris (FR)
- B. Hollenbeck, Ann Arbor (US)
- M. Valerio, Lausanne (CH)

**Aims and objectives of this session**
The aim of this session is to update delegates on the use of focal therapy and non-whole gland treatments.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1. **Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study**
   By: Shanmugabavan Y.1, Bass E.1, Hulme A.2, Freeman A.3, Brew-Graves C.1, Potyka I.1, Ramachandran N.4, Emberton M.1, Ahmed H.U.1
   **Institutes:** University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, Sophiris Bio Corporation, California, United States of America, University College London Hospital, Dept. of Histopathology, London, United Kingdom, University College London Hospital, Dept. of Radiology, London, United Kingdom

2. **Impact of the use of N2O for general anesthesia during high intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer**
   By: Potiron E.1, Lacoste J.2, Le Goguic G.2, Rousseau T.2, Nevoux P.2
   **Institutes:** Clinique Urologique Nantes Atlantis, Dept. of Urology, Saint Herblain, France, Clinique Urologique Nantes Atlantis, Dept. of Urology, Saint Herblain, France

3. **Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy**
   By: Garcia Barreras S.1, Sanchez-Salas R.1, Sivararam A.2, Secin F.3, Redondo C.1, Velilla G.1, Barret E.1, Nunes-Silva I.1, Srourgi V.1, Baghdadi M.1, Galiano M.1, Rozet F.1, Cathala N.1, Mombet A.1, Prapotnich D.1, Cathelineau X.1
   **Institutes:** Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, Memorial Sloan Kettering, Dept. of Urology, New York, United States of America, CEMIC, Dept. of Urology, Buenos Aires, Argentina

4. **A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study**
   By: Leslie T.1, Elliott D.3, Le Conte S.1, Brewster S.2, Sooriakumaran P.1, Bryant R.1, Dudderidge T.4, Rosario D.5, Catto J.8, Hindley R.6, Emberton M.7, Ahmed H.7, Donovan J.2, Hamdy F.1
   **Institutes:** Oxford University - Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, University of Bristol, Dept. of Social and Community Medicine, Bristol, United Kingdom, University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, Basingstoke and North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom, University College London Hospital, Dept. of Urology, London, United Kingdom

5. **First repeated biopsy represents the most informative predictor of progression-free survival at 3**
763 A nomogram for prediction of local cancer recurrence after primary prostate cryoablation
By: El Shafei A. 1, Tay K.J. 2, Ross A. 3, Given R. 4, Parsons J.K. 5, Mouraviev V. 6, Polascik T. 2, Jones J.S. 1
Institutes: 1 Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, 2Duke Cancer Institute, Dept. of Urology, Durham, United States of America, 3The Johns Hopkins Medical Institutions, Dept. of Urology, Baltimore, United States of America, 4Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, 5UC San Diego Health System, Dept. of Urology, San Diego, United States of America, 6Global Robotics Institute, Dept. of Urology, Celebration, United States of America

764 MRI-guided transurethral ultrasound ablation in patients with localized prostate cancer: 24-month outcomes of a prospective phase I clinical trial
Institutes: 1Western University, Dept. of Urology, London, Canada, 2Beamont Health System, Department of Urology, Dept. of Urology and Radiology, Royal Oak, United States of America, 3German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, 4Profound Medical Inc., Dept. of Engineering, Toronto, Canada

765 Withdrawn
By: 
Institutes:

766 Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymphvessel invasion and shorten biochemical recurrence-free survival periods
By: Miyata Y. 1, Mochizuki Y. 1, Shida Y. 1, Matsuo T. 1, Hakariya T. 1, Ohba K. 1, Furusato B. 2, Fukuoka J. 2, Sakai H. 1
Institutes: 1Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, 2Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

767 Salvage prostate cryoablation in older men
By: Parsons K. 2, Ross A. 3, El Shafei A. 1, Hatem A. 1, Cotta B. 2, Tay K.J. 4, Polascik T. 2, Given R. 5, Mouraviev V. 6, Jones J.S. 1
Institutes: 1Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, 2UC San Diego Health System, Dept. of Urology, San Diego, California, United States of America, 3The Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, United States of America, 4Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, 5Duke Cancer Institute, Dept. of Urology, Durham, United States of America, 6Global Robotics Institute, Dept. of Urology, Celebration, United States of America

768 Current national trends in the management of locally advanced prostate cancer with radical therapies: Results from the English National Prostate Cancer Audit
By: Sujenthiran A. 1, Nossiter J. 1, Charman S. 1, Aggarwal A. 1, Cathcart P. 2, Payne H. 3, Clarke N. 4, Van Der Meulen J. 1
Institutes: 1Royal College of Surgeons, Clinical Effectiveness Unit, London, United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3University College London Hospitals, Dept. of Oncology, London, United Kingdom, 4The Christie and Salford Royal NHS Foundation Trusts, Dept. of Urology, London, United Kingdom
**V46**

**MRI/US fusion office-based targeted cryoablation with local anesthesia**

**By:** Bianco F., Lozano-Kaplun S., Cedeno J., Barashi N., Scher J., Kaufman A., Lopez A., Nicholson M.

**Institutes:** Urological Research Network, Dept. of Urology, Miami Lakes, United States of America

**17:00 - 17:07**

**Summary**

E. Barret, Paris (FR)